Despite considerable advances in treatment approaches in the past two decades, multiple
myeloma remains an incurable disease. Treatments for myeloma continue to evolve with …

With the successful treatment of B-cell lymphomas using rituximab, a monoclonal antibody
targeting CD20, novel immunotherapies have developed rapidly in recent years. Immune …

Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow
microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase …

Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier
monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no …

Immune checkpoint blockade has driven a revolution in modern oncology, and robust drug
development of immune checkpoint inhibitors is underway in both solid tumors and …

Despite significant improvements in the overall survival of patients with multiple myeloma
(MM) over the past 15 years, the disease remains incurable. Treatment options are limited …

Immunotherapy has played an important part in improving the life of patients with
lymphoproliferative diseases especially since the addition of rituximab to chemotherapy in …

Background: Multiple myeloma (MM) is an incurable B-cell malignancy, but with the
emergence of immunotherapy, a potential cure is hopeful. The individualized interaction …

多发性骨髓瘤(MM) 是一种浆细胞恶性克隆增殖性疾病, 近年来, 蛋白酶体抑制剂,
免疫调节剂在多发性骨髓瘤中的应用明显延长了患者的生存期并提高了生存质量 …

Multiple myeloma is the second most common hematological malignancy in adults,
accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based …